---
document_datetime: 2025-12-02 04:50:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kymriah.html
document_name: kymriah.html
version: success
processing_time: 0.1282424
conversion_datetime: 2025-12-27 21:09:52.642839
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kymriah

[RSS](/en/individual-human-medicine.xml/66212)

##### Authorised

This medicine is authorised for use in the European Union

tisagenlecleucel Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kymriah](#news-on)
- [More information on Kymriah](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Kymriah is a medicine for treating the following types of blood cancer:

• B-cell acute lymphoblastic leukaemia (ALL), in children and young adults up to 25 years of age whose cancer did not respond to previous treatment, has come back two or more times, or has come back after a transplant of stem cells;

• Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in adults whose cancer has come back or did not respond after two or more previous treatments.

Kymriah is a type of advanced therapy medicine called a 'gene therapy product'. This is a type of medicine that works by delivering genes into the body.

The blood cancers that Kymriah is used to treat are rare, and Kymriah was designated an 'orphan medicine' (a medicine used in rare diseases) for B-cell ALL on 29 April 2014, DLBCL on 14 October 2016 and FL on 19 July 2021.

Kymriah contains the active substance tisagenlecleucel (consisting of genetically modified white blood cells).

Expand section

Collapse section

## How is Kymriah used?

Kymriah is prepared using the patient's own white blood cells which are extracted from the blood and genetically modified in the laboratory.

It is given as a single infusion (drip) into a vein and must only be given to the patient whose cells were used to make it. Before having Kymriah, the patient should have a short course of chemotherapy to clear away their white blood cells and just before the infusion, the patient is given paracetamol and an antihistamine medicine to reduce the risk of reactions to the infusion.

A medicine called tocilizumab and emergency equipment must be available in case the patient has a potentially serious side effect called cytokine release syndrome, a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure (see risks section below).

Patients should be closely monitored for 10 days after treatment for side effects and are advised to stay close to a specialist hospital for at least 4 weeks after treatment.

For more information about using Kymriah, see the package leaflet or contact your doctor or pharmacist.

## How does Kymriah work?

Kymriah contains the patient's own T cells (a type of white blood cell) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR). CAR can attach to another protein on the surface of cancer cells called CD19.

When Kymriah is given to the patient, the modified T cells attach to and kill the cancer cells, thereby helping to clear the cancer from the body.

## What benefits of Kymriah have been shown in studies?

**B-cell ALL**

The main study of Kymriah in B-cell ALL involved 92 children and young adults (3-25 years of age) whose cancer had come back after previous treatment or did not respond to treatment. Around 66% of patients had a complete response (which means they had no signs of the cancer left) in the 3 months after treatment. This was better than results seen with the cancer medicines clofarabine, blinatumomab or a combination of clofarabine, cyclophosphamide and etoposide. Twelve months after treatment, the likelihood of survival was 70%.

**DLBCL**

The main study of Kymriah in DLBCL involved 165 patients who had at least 2 previous treatments and could not have a stem cell transplant. Around 24% of patients had a complete response and 34% had at least a partial response after at least 3 months. These results were comparable to those from studies of patients receiving standard cancer treatments. Twelve months after treatment, the likelihood of survival was 40%. The majority of patients who responded to Kymriah continued to have a response after 19 months.

**FL**

The main study for FL involved 98 patients whose cancer had come back after previous treatment or did not respond to treatment. Patients had at least 2 previous treatments. Around 69% of patients had a complete response 3 months after treatment.

## What are the risks associated with Kymriah?

Serious side effects occur in most patients. The most common serious side effects are cytokine release syndrome and decreases in platelets (components that help the blood to clot), haemoglobin (the protein found in red blood cells that carries oxygen around the body) or white blood cells including neutrophils and lymphocytes.

In addition, serious infections are very common side effects in patients treated for DLBCL and FL.

For the full list of side effects and restrictions with Kymriah, see the package leaflet

## Why is Kymriah authorised in the EU?

B-cell ALL patients have poor outcomes and improvements with Kymriah were better than with other medicines for this condition. In patients with DLBCL treated with Kymriah, the results were similar to other treatments but ongoing study data indicate that the effects last longer. Kymriah was also shown to produce a robust response in patients with FL.  Serious side effects, occur in most patients, and can include cytokine release syndrome. However these are manageable if the appropriate measures are in place (see below). The European Medicines Agency therefore decided that Kymriah's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Kymriah?

The company that markets Kymriah must ensure that hospitals where Kymriah is given have appropriate expertise, facilities and training. Tocilizumab must be available in case of cytokine release syndrome. The company must provide educational materials for healthcare professionals and patients about possible side effects, especially cytokine release syndrome.

The company must carry out several studies to obtain more information on Kymriah including its safety and effectiveness in the long term and in B-cell ALL patients under 3 years of age.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kymriah have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Kymriah are continuously monitored. Side effects reported with Kymriah are carefully evaluated and any necessary action taken to protect patients.

## Other information about Kymriah

Kymriah received a marketing authorisation valid throughout the EU on 23 August 2018.

Kymriah : EPAR - Medicine overview

Reference Number: EMA/188757/2022

English (EN) (144.91 KB - PDF)

**First published:** 19/09/2018

**Last updated:** 19/05/2022

[View](/en/documents/overview/kymriah-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-805)

български (BG) (163.22 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/bg/documents/overview/kymriah-epar-medicine-overview_bg.pdf)

español (ES) (134.45 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/es/documents/overview/kymriah-epar-medicine-overview_es.pdf)

čeština (CS) (159.58 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/cs/documents/overview/kymriah-epar-medicine-overview_cs.pdf)

dansk (DA) (132.62 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/da/documents/overview/kymriah-epar-medicine-overview_da.pdf)

Deutsch (DE) (138.39 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/de/documents/overview/kymriah-epar-medicine-overview_de.pdf)

eesti keel (ET) (122.1 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/et/documents/overview/kymriah-epar-medicine-overview_et.pdf)

ελληνικά (EL) (162.38 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/el/documents/overview/kymriah-epar-medicine-overview_el.pdf)

français (FR) (136.26 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/fr/documents/overview/kymriah-epar-medicine-overview_fr.pdf)

hrvatski (HR) (158.1 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/hr/documents/overview/kymriah-epar-medicine-overview_hr.pdf)

italiano (IT) (132.32 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/it/documents/overview/kymriah-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (174.18 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/lv/documents/overview/kymriah-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (158.47 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/lt/documents/overview/kymriah-epar-medicine-overview_lt.pdf)

magyar (HU) (158.38 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/hu/documents/overview/kymriah-epar-medicine-overview_hu.pdf)

Malti (MT) (160.79 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/mt/documents/overview/kymriah-epar-medicine-overview_mt.pdf)

Nederlands (NL) (133.65 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/nl/documents/overview/kymriah-epar-medicine-overview_nl.pdf)

polski (PL) (160.04 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/pl/documents/overview/kymriah-epar-medicine-overview_pl.pdf)

português (PT) (135.41 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/pt/documents/overview/kymriah-epar-medicine-overview_pt.pdf)

română (RO) (157.44 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/ro/documents/overview/kymriah-epar-medicine-overview_ro.pdf)

slovenčina (SK) (158.04 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/sk/documents/overview/kymriah-epar-medicine-overview_sk.pdf)

slovenščina (SL) (155.47 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/sl/documents/overview/kymriah-epar-medicine-overview_sl.pdf)

Suomi (FI) (132.18 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/fi/documents/overview/kymriah-epar-medicine-overview_fi.pdf)

svenska (SV) (133.22 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

19/05/2022

[View](/sv/documents/overview/kymriah-epar-medicine-overview_sv.pdf)

Kymriah : EPAR - Risk-management-plan sumary

English (EN) (25.94 MB - PDF)

**First published:** 19/09/2018

**Last updated:** 07/05/2025

[View](/en/documents/rmp-summary/kymriah-epar-risk-management-plan-sumary_en.pdf)

## Product information

Kymriah : EPAR - Product Information

English (EN) (511.13 KB - PDF)

**First published:** 19/09/2018

**Last updated:** 06/11/2025

[View](/en/documents/product-information/kymriah-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-268)

български (BG) (639.76 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/bg/documents/product-information/kymriah-epar-product-information_bg.pdf)

español (ES) (580.91 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/es/documents/product-information/kymriah-epar-product-information_es.pdf)

čeština (CS) (627.06 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/cs/documents/product-information/kymriah-epar-product-information_cs.pdf)

dansk (DA) (594.11 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/da/documents/product-information/kymriah-epar-product-information_da.pdf)

Deutsch (DE) (621.04 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/de/documents/product-information/kymriah-epar-product-information_de.pdf)

eesti keel (ET) (573.99 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/et/documents/product-information/kymriah-epar-product-information_et.pdf)

ελληνικά (EL) (659.38 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/el/documents/product-information/kymriah-epar-product-information_el.pdf)

français (FR) (605.73 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/fr/documents/product-information/kymriah-epar-product-information_fr.pdf)

hrvatski (HR) (610.8 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/hr/documents/product-information/kymriah-epar-product-information_hr.pdf)

íslenska (IS) (567.41 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/is/documents/product-information/kymriah-epar-product-information_is.pdf)

italiano (IT) (596.22 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/it/documents/product-information/kymriah-epar-product-information_it.pdf)

latviešu valoda (LV) (620 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/lv/documents/product-information/kymriah-epar-product-information_lv.pdf)

lietuvių kalba (LT) (587.67 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/lt/documents/product-information/kymriah-epar-product-information_lt.pdf)

magyar (HU) (638.26 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/hu/documents/product-information/kymriah-epar-product-information_hu.pdf)

Malti (MT) (680.38 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/mt/documents/product-information/kymriah-epar-product-information_mt.pdf)

Nederlands (NL) (609.84 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/nl/documents/product-information/kymriah-epar-product-information_nl.pdf)

norsk (NO) (547.93 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/no/documents/product-information/kymriah-epar-product-information_no.pdf)

polski (PL) (644.52 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/pl/documents/product-information/kymriah-epar-product-information_pl.pdf)

português (PT) (586.12 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/pt/documents/product-information/kymriah-epar-product-information_pt.pdf)

română (RO) (638.1 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/ro/documents/product-information/kymriah-epar-product-information_ro.pdf)

slovenčina (SK) (652.25 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/sk/documents/product-information/kymriah-epar-product-information_sk.pdf)

slovenščina (SL) (635.82 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/sl/documents/product-information/kymriah-epar-product-information_sl.pdf)

Suomi (FI) (575.88 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/fi/documents/product-information/kymriah-epar-product-information_fi.pdf)

svenska (SV) (538.32 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

06/11/2025

[View](/sv/documents/product-information/kymriah-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000309349 06/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kymriah : EPAR - All Authorised presentations

English (EN) (90.67 KB - PDF)

**First published:** 19/09/2018

**Last updated:** 01/04/2020

[View](/en/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-953)

български (BG) (93.16 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/bg/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_bg.pdf)

español (ES) (90.39 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/es/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_es.pdf)

čeština (CS) (90.68 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/cs/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (88.71 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/da/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (87.94 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/de/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (85.01 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/et/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (93.93 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/el/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_el.pdf)

français (FR) (87.19 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/fr/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (88.69 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/hr/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (93.85 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/is/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_is.pdf)

italiano (IT) (86.27 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/it/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (89.42 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/lv/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (90.71 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/lt/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (94.55 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/hu/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (91.41 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/mt/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (89.79 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/nl/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (88.6 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/no/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_no.pdf)

polski (PL) (91.4 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/pl/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_pl.pdf)

português (PT) (87.42 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/pt/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_pt.pdf)

română (RO) (88.91 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/ro/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (90.45 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/sk/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (87.42 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/sl/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (84.57 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/fi/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (90.44 KB - PDF)

**First published:**

19/09/2018

**Last updated:**

01/04/2020

[View](/sv/documents/all-authorised-presentations/kymriah-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kymriah Active substance tisagenlecleucel International non-proprietary name (INN) or common name tisagenlecleucel Therapeutic area (MeSH)

- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, Large B-Cell, Diffuse

Anatomical therapeutic chemical (ATC) code L01XL04

### Pharmacotherapeutic group

Other antineoplastic agents

### Therapeutic indication

Kymriah is indicated for the treatment of:

• Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse.

• Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy.

• Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

## Authorisation details

EMA product number EMEA/H/C/004090

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 27/06/2018 Marketing authorisation issued 23/08/2018 Revision 23

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kymriah : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (138.93 KB - PDF)

**First published:** 15/05/2025

**Last updated:** 06/11/2025

[View](/en/documents/procedural-steps-after/kymriah-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Kymriah : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (332.8 KB - PDF)

**First published:** 01/04/2020

**Last updated:** 26/06/2025

[View](/en/documents/procedural-steps-after/kymriah-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Kymriah-H-C-PSUSA-00010702-202408 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/214537/2025

English (EN) (117.2 KB - PDF)

**First published:** 26/06/2025

[View](/en/documents/scientific-conclusion/kymriah-h-c-psusa-00010702-202408-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Kymriah-H-C-004090-P46-022 : EPAR - Assessment report

Adopted

Reference Number: EMA/62477/2024

English (EN) (817.78 KB - PDF)

**First published:** 12/02/2024

[View](/en/documents/variation-report/kymriah-h-c-004090-p46-022-epar-assessment-report_en.pdf)

Kymriah-H-C-4090-II-56: EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/833142/2022

English (EN) (5.51 MB - PDF)

**First published:** 24/10/2022

[View](/en/documents/variation-report/kymriah-h-c-4090-ii-56-epar-assessment-report-variation_en.pdf)

Kymriah-H-C-4090-P46-017 : EPAR - Assessment report

Adopted

Reference Number: EMA/800781/2022

English (EN) (682.76 KB - PDF)

**First published:** 24/10/2022

[View](/en/documents/variation-report/kymriah-h-c-4090-p46-017-epar-assessment-report_en.pdf)

Kymriah : Orphan maintenance assessment report (post authorisation)

Adopted

Reference Number: EMA/OD/0000054173

English (EN) (742.71 KB - PDF)

**First published:** 19/05/2022

[View](/en/documents/orphan-maintenance-report-post/kymriah-orphan-maintenance-assessment-report-post-authorisation_en.pdf)

Kymriah-H-C-4090-II-0044 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/211805/2022

English (EN) (16.22 MB - PDF)

**First published:** 19/05/2022

[View](/en/documents/variation-report/kymriah-h-c-4090-ii-0044-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of opinion for Kymriah (II-44)

Adopted

Reference Number: EMA/CHMP/167689/2022

English (EN) (155.17 KB - PDF)

**First published:** 25/03/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-opinion-kymriah-ii-44_en.pdf)

Kymriah-H-C-4090-P46-012.1 : EPAR - Assessment report

Adopted

Reference Number: EMA/104600/2022

English (EN) (1.43 MB - PDF)

**First published:** 17/02/2022

[View](/en/documents/variation-report/kymriah-h-c-4090-p46-0121-epar-assessment-report_en.pdf)

Kymriah-H-C-4090-P46-012 : EPAR - Assessment report

Adopted

Reference Number: EMA/617616/2021

English (EN) (5.49 MB - PDF)

**First published:** 29/10/2021

[View](/en/documents/variation-report/kymriah-h-c-4090-p46-012-epar-assessment-report_en.pdf)

Kymriah-H-C-4090-P46-011 : EPAR - Assessment report

Adopted

Reference Number: EMA/61202/2020

English (EN) (2.22 MB - PDF)

**First published:** 29/06/2020

[View](/en/documents/variation-report/kymriah-h-c-4090-p46-011-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Kymriah : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/581378/2018

English (EN) (355.42 KB - PDF)

**First published:** 19/09/2018

**Last updated:** 19/09/2018

[View](/en/documents/orphan-maintenance-report/kymriah-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Kymriah : EPAR - Public assessment report

Adopted

Reference Number: EMA/485563/2018

English (EN) (7.25 MB - PDF)

**First published:** 19/09/2018

**Last updated:** 19/09/2018

[View](/en/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Kymriah

Adopted

Reference Number: EMA/CHMP/289459/2018

English (EN) (72.2 KB - PDF)

**First published:** 29/06/2018

**Last updated:** 29/06/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-kymriah_en.pdf)

#### News on Kymriah

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 June 2024](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024) 14/06/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 March 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-march-2022) 25/03/2022

[First two CAR-T cell medicines recommended for approval in the European Union](/en/news/first-two-car-t-cell-medicines-recommended-approval-european-union) 29/06/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-june-2018) 29/06/2018

#### More information on Kymriah

- [EU/3/14/1266 - orphan designation for treatment of B-lymphoblastic leukaemia/lymphoma](/en/medicines/human/orphan-designations/eu-3-14-1266)
- [EMEA-001654-PIP01-14-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001654-pip01-14-m04)
- [EMEA-001654-PIP02-17-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001654-pip02-17-m01)
- [Abecma / Breyanzi / Carvykti / Kymriah / Tecartus / Yescarta - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/abecma-breyanzi-carvykti-kymriah-tecartus-yescarta)
- [Registry study to assess the long-term safety of patients with B lymphocyte malignancies treated with tisagenlecleucel - post-authorisation study](https://catalogues.ema.europa.eu/study/42020)

#### Topics

- [Advanced therapies](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A42)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 06/11/2025

## Share this page

[Back to top](#main-content)